Combination treatment for recurring brain cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of glioblastoma that has come back after treatment.
- Your tumor must not have a certain genetic marker called MGMT methylation.
- You must have a tumor that can be measured on an MRI scan.
- Your overall health must be good enough for you to be up and about (Karnofsky score of 70 or higher).
- Your blood counts and liver/kidney function must be within acceptable ranges.
- You cannot have had certain previous treatments for this cancer, like bevacizumab or lomustine.
- You must not have significant heart disease or a recent heart attack or stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of two drugs—vebreltinib and temozolomide—for people with a type of brain cancer called glioblastoma. It is for those who have already had surgery to remove as much of the tumor as possible.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests whether adding cannabinoid medicine to temozolomide helps people whose glioblastoma (GBM) has returned. It compares temozolomide plus cannabinoids versus temozolomide alone, using blinded treatment so neither you nor the team knows which option you get.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.